---
title: "Key facts: Aficamten approved US, EU, China; launch outpaces targets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287021761.md"
description: "CYTK: MYKORZO (aficamten) has received approval for oHCM in the US, EU, and China, with early sales exceeding expectations. Trials indicate strong efficacy and safety. The company is expanding its indications and global launches, with significant physician uptake and patient persistency. European expansion is in progress, and management anticipates minimal impact from MFN."
datetime: "2026-05-20T07:14:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287021761.md)
  - [en](https://longbridge.com/en/news/287021761.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287021761.md)
---

# Key facts: Aficamten approved US, EU, China; launch outpaces targets

-   CYTK: MYQORZO (aficamten) gained approval for oHCM in US, EU and China. Early sales rising; trials show strong efficacy and safety. Company pursuing more indications and global launches.1
-   CYTK: MYKORZO launch outpacing targets with strong physician uptake, high patient persistency, advancing payer access, European expansion underway, and management expects minimal MFN impact2

### Related Stocks

- [CYTK.US](https://longbridge.com/en/quote/CYTK.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Investors Purchase High Volume of Call Options on Cytokinetics (NASDAQ:CYTK)](https://longbridge.com/en/news/286147431.md)
- [Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026 | CYTK Stock News](https://longbridge.com/en/news/285958342.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Zydus buys US specialty drugmaker Assertio in Rs 1,600 crore all-cash deal](https://longbridge.com/en/news/286352725.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)